The coronary sinus reducer: clinical evidence and technical aspects

References

• Jolicoeur EM, Granger CB, Henry TD, et al. Clinical and research issues regarding chronic advanced coronary artery disease: part I: contemporary and emerging therapies. Am Heart J. 2008;155:418–434.
   PubMed Web of Science ®Google Scholar
• Jolicoeur EM, Ohman EM, Temple R, et al. Clinical and research issues regarding chronic advanced coronary artery disease part II: trial design, outcomes, and regulatory issues. Am Heart J. 2008;155:435–444.
   PubMed Web of Science ®Google Scholar
• McGillion M, Arthur HM, Cook A, et al. Management of patients with refractory angina: canadian cardiovascular society/canadian pain society joint guidelines. Can J Cardiol. 2012;28(2 Suppl.):S20–S41.
   PubMed Web of Science ®Google Scholar
• Jolicoeur EM, Cartier R, Henry TD, et al. Patients with coronary refractory artery disease unsuitable for revascularization: definition, general principles and a classification. Can J Cardiol. 2012;28(Suppl.):S50–S59.
   PubMedGoogle Scholar
• Mannheimer C, Camici P, Chester MR, et al. The problem of chronic refractory angina; report from the ESC joint study group on the treatment of refractory angina. Eur Heart J. 2002;23:355–370.
   PubMed Web of Science ®Google Scholar
• Camici PG, Crea F. Coronary microvascular dysfunction. N Engl J Med. 2007;356:830–840.
   PubMed Web of Science ®Google Scholar
• Crea F, Camici PG. Coronary microvascular dysfunction: an update. Eur Heart J. 2014;35:1101–1111.
   PubMed Web of Science ®Google Scholar
• Mukherjee D, Bhatt DL, Roe MT, et al. Direct myocardial revascularization and angiogenesis—how many patients might be eligible? am. J Cardiol. 1999;84:598–600.
   Web of Science ®Google Scholar
• Williams B, Menon M, Satran D, et al. Patients with coronary
artery disease not amenable to traditional revascularization: prevalence and 3-year mortality. Catheter Cardiovasc Interv. 2010;75:886–891.
   PubMed Web of Science ®Google Scholar
• Montalescot G, Sechtem U, Achenbach S, et al.; Task Force Members. ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J. 2013;34(38):2949–3003.
   Web of Science ®Google Scholar
• Mukherjee D, Comella K, Bhatt DL, et al. Clinical outcome of a cohort of patients eligible for therapeutic angiogenesis or transmyocardial revascularization. Am Heart J. 2001;142:72–74.
   PubMed Web of Science ®Google Scholar
• Serruys PW. Assessing percutaneous intervention: re-appraising the significance of residual angina. EuroIntervention. 2015 Mar;10(11):1253.
   PubMed Web of Science ®Google Scholar
• Frazier OH, March RJ, Horvath KA. Transmyocardial revascularization with a carbon dioxide laser in patients with end-stage coronary artery disease. N Engl J Med. 1999;341:1021–1028.
   PubMed Web of Science ®Google Scholar
• Oesterle SN, Sanborn TA, Ali N, et al. Percutaneous transmyocardial laser revascularization for severe angina: the PACIFIC randomized trial. Lancet. 2000;356:1705–1710.
   PubMed Web of Science ®Google Scholar
• Losordo DW, Henry TD, Davidson C, et al. Intramyocardial, autologous CD34+ cell therapy for refractory angina. Circ Res. 2011;109:428–436.
   PubMed Web of Science ®Google Scholar
• Grines CL, Watkins MW, Mahmarian JJ, et al. A randomized, double-blind, placebo-controlled trial of Ad5FGF- 4 gene therapy and its effect on myocardial perfusion in patients with stable angina. J Am Coll Cardiol. 2003;42:1339–1347.
   PubMed Web of Science ®Google Scholar
• Kastrup J, Jørgensen E, Ruck A, et al. Direct intramyocardial plasmid vascular endothelial growth factor-A165 gene therapy in patients with stable severe angina pectoris: a randomized double-blind placebo-controlled study: the euroinject one trial. J Am Coll Cardiol. 2005;45:982–988.
   PubMed Web of Science ®Google Scholar
• Leon MB, Kornowski R, Downey WE, et al. A blinded, randomized, placebo-controlled trial of percutaneous laser myocardial revascularization to improve angina symptoms in patients with severe coronary disease. J Am Coll Cardiol. 2005;46:1812–1819.
   PubMed Web of Science ®Google Scholar
• Simons M, Annex BH, Laham RJ, et al. Pharmacological treatment of coronary artery disease with recombinant fibroblast growth factor-2: double-blind, randomized, controlled clinical trial. Circulation. 2002;105:788–793.
   PubMed Web of Science ®Google Scholar
• Stewart DJ, Hilton JD, Arnold JM, et al. Angiogenic gene therapy in patients with non revascularizable ischemic heart disease: a phase 2 randomized, controlled trial of AdVEGF121 (AdVEGF121) versus maximum medical treatment. Gene Ther. 2006;13:1503–1511.
   PubMed Web of Science ®Google Scholar
• Stewart DJ, Kutryk MJ, Fitchett D, et al. VEGF gene therapy fails to improve perfusion of ischemic myocardium in patients with advanced coronary disease: results of the NORTHERN trial. Mol Ther. 2009;17:1109–1115.
   PubMed Web of Science ®Google Scholar
• Kandzari DE, Lam LC, Eisenstein EL, et al. Advanced coronary artery disease: appropriate end points for trials of novel therapies. Am Heart J. 2001;142:843–851.
   PubMed Web of Science ®Google Scholar
• Cavender MA, Alexander KP, Broderick S, et al. Long-term morbidity and mortality among medically managed patients with angina and multivessel coronary artery disease. Am Heart J. 2009;158:933–940.
   PubMed Web of Science ®Google Scholar
• Henry TD, Satran D, Hodges JS, et al. Long-term survival in patients with refractory angina. Eur Heart J. 2013;34:2683–2688.
   PubMed Web of Science ®Google Scholar
• Povsic TJ, Broderick S, Anstrom KJ, et al. Predictors of long-term clinical endpoints in patients with refractory angina. J Am Heart Assoc. 2015;4:2.
   Web of Science ®Google Scholar
• Mukherjee D. Management of refractory angina in the contemporary era. Eur Heart J. 2013;34:2655–2657.
   PubMed Web of Science ®Google Scholar
• Kiernan TJ, Boilson BA, Sandhu GS, et al. Non revascularizable coronary artery disease following coronary artery bypass graft surgery: a population-based study in Olmsted County, Minnesota. Coron Artery Dis. 2009;20(2):106–111.
   PubMed Web of Science ®Google Scholar
• Gowda RM, Khan IA, Punukollu G, et al. Treatment of refractory angina pectoris. Int J Cardiol. 2005;11(101):1–7.
   Google Scholar
• Rayner-Hartley E, Sedlak T. Ranolazine: a contemporary review. J Am Heart Assoc. 2016;5(3).
   Web of Science ®Google Scholar
• Gibbons RJ, Abrams J, Chatterjee K, et al. ACC/AHA 2002 guideline update for the management of patients with chronic stable angina—summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients with Chronic Stable Angina). J Am Coll Cardiol. 2003;41:159–168.
   PubMedGoogle Scholar
• Heidenreich PA, McDonald KM, Hastie T, et al. Meta-analysis of trials comparing β-blockers, calcium antagonists, and nitrates for stable angina. JAMA. 1999;281:1927–1936.
   PubMed Web of Science ®Google Scholar
• Kones R. Recent advances in the management of chronic stable angina. II. Anti-ischemic therapy, options for refractory angina, risk factor reduction, and revascularization. Vasc Health Risk Manag. 2010;6:749–774.
   PubMedGoogle Scholar
• Henderson RA, O’Flynn N. Management of stable angina: summary of NICE guidance. Heart. 2012;98:500–507.
   PubMed Web of Science ®Google Scholar
• Husted SE, Ohman EM. Pharmacological and emerging therapies in the treatment of chronic angina. Lancet. 2015;386:691–701.
   PubMed Web of Science ®Google Scholar
• IONA Study Group. Effect of nicorandil on coronary events in patients with stable angina: the Impact of Nicorandil in Angina (IONA) randomised trial. Lancet. 2002;359:1269–1275.
   PubMed Web of Science ®Google Scholar
• Stone PH, Gratsiansky NA, Blokhin A, et al. ERICA Investigators. Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (Efficacy of Ranolazine in Chronic Angina) trial. J Am Coll Cardiol. 2006;48:566–575.
   PubMed Web of Science ®Google Scholar
• Chaitman BR, Skettino SL, Parker JO, et al. MARISA Investigators. Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. J Am Coll Cardiol. 2004;43:1375–1382.
   PubMed Web of Science ®Google Scholar
• Weisz G, Généreux P, Iniguez A, et al. Ranolazine in patients with incomplete revascularisation after percutaneous coronary intervention (RIVER-PCI): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet. 2016;387(10014):136–145.
   PubMed Web of Science ®Google Scholar
• Tardif J, Ford I, Tendera M, et al. For the INITIATIVE investigators, Efficacy of ivabradine, a new selective If inhibitor, compared with atenolol in patients with chronic stable angina. Eur Heart J. 2005;26:2529–2536.
   PubMed Web of Science ®Google Scholar
• Fox K, Ford I, Steg PG, et al. BEAUTIFUL investigators, Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372:807–816.
   PubMed Web of Science ®Google Scholar
• Noman A, Ang DS, Ogston S, et al. Effect of high-dose allopurinol on exercise in patients with chronic stable angina: a randomised, placebo controlled crossover trial. Lancet. 2010;375:2161–2167.
   PubMed Web of Science ®Google Scholar
• Szwed H, Sadowski Z, Elikowski W, et al. Combination treatment in stable effort angina using trimetazidine and metoprolol: results of a randomized, double-blind, multicentre study (TRIMPOL II). Eur Heart J. 2001;22:2267–2274.
   PubMed Web of Science ®Google Scholar
• Labrou A, Giannoglou G, Zioutas D, et al. Trimetazidine administration minimizes myocardial damage and improves left ventricular function after percutaneous coronary intervention. Am J Cardiovasc Drugs. 2007;7:143–150.
   PubMed Web of Science ®Google Scholar
• Lee L, Campbell R, Scheuermann-Freestone M, et al. Metabolic modulation with perhexiline in chronic heart failure: a randomized, controlled trial of short-term use of a novel treatment. Circulation. 2005;112:3280–3288.
   PubMed Web of Science ®Google Scholar
• Vicari RM, Chaitman B, Keefe D, et al. Efficacy and safety of fasudil in patients with stable angina: A double-blind, placebo-controlled, phase 2 trial. J Am Coll Cardiol. 2005;46:1803–1811.
   PubMed Web of Science ®Google Scholar
• Mischie A, Chanseaume S, Gaspard P, et al. Oral sirolimus: A possible treatment for refractory angina pectoris in the elderly. Int J Cardiol. 2016;222:1097-1104.
   PubMed Web of Science ®Google Scholar
• Arora RR, Chou TM, Jain D, et al. The multicenter study of enhanced external counterpulsation (MUST-EECP): effect of EECP on exercise-induced myocardial ischemia and anginal episodes. J Am Coll Cardiol. 1999;33:1833–1840.
   PubMed Web of Science ®Google Scholar
• Buiten MS, DeJongste MJ, Beese U, et al. Subcutaneous electrical nerve stimulation: a feasible and new method for the treatment of patients with refractory angina. Neuromodulation. 2011;14:258–265.
   PubMed Web of Science ®Google Scholar
• Eddicks S, Maier-Hauff K, Schenk M, et al. Thoracic spinal cord stimulation improves functional status and relieves symptoms in patients with refractory angina pectoris: the first placebo-controlled randomized study. Heart. 2007;93:585–590.
   PubMed Web of Science ®Google Scholar
• Lanza GA, Grimaldi R, Greco S, et al. Spinal cord stimulation for the treatment of refractory angina pectoris: a multicenter randomized single-blind study (the SCS-ITA trial). Pain. 2011;152:45–52.
   PubMed Web of Science ®Google Scholar
• Ekre O, Eliasson T, Norrsell H, et al. Long-term effects of spinal cord stimulation and coronary artery bypass grafting on quality of life and survival in the ESBY study. Eur Heart J. 2002;23(24):1938–1945.
   PubMed Web of Science ®Google Scholar
• Oesterle S, Sanborn TA, Ali N, et al. Percutaneous transmyocardial laser revascularisation for severe angina: the PACIFIC randomized trial. Potential Class Improvement From Intramyocardial Channels. Lancet. 2000;356:1705–1710.
   PubMed Web of Science ®Google Scholar
• Leon MB, Kornowski R, Downey WE, et al. A blinded, randomized, placebo-controlled trial of percutaneous laser myocardial revascularization to improve angina symptoms in patients with severe coronary disease. J Am Coll Cardiol. 2005;46:1812–1819.
   PubMed Web of Science ®Google Scholar
• Wang Y, Guo T, Ma TK, et al. A modified regimen of extracorporeal cardiac shock wave therapy for treatment of coronary artery disease. Cardiovasc Ultrasound. 2012;10:35.
   PubMed Web of Science ®Google Scholar
• Slavich M, Ancona F, Margonato A. Extracorporeal shockwave myocardial revascularization therapy in refractory angina patients. Int J Cardiol. 2015;194:93.
   PubMed Web of Science ®Google Scholar
• Loukas M, Bilinsky S, Bilinsky E. el-Sedfy A, Anderson RH. Cardiac veins: a review of the literature. Clin Anat. 2009;22:129–145.
   PubMed Web of Science ®Google Scholar
• Gross L, Blum L, Silverman G. Experimental attempts to increase blood supply in the dogs heart by means of coronary sinus occlusion. J Exp Med. 1937;65:91–108.
   PubMedGoogle Scholar
• Beck CS, Mako AE. Venous stasis in coronary circulation. An experimental study. Amer Heart J. 1941;21:767–779.
   Google Scholar
• Wising PJ. The Beck-I operation for angina pectoris: medical aspects. Acta Medica Scandinavia. 1963;174:93–98.
   PubMedGoogle Scholar
• Beck CS, Leighninger DS. Scientific basis for the surgical treatment of coronary artery disease. J Am Med Assoc. 1955;159:1264–1271.
   PubMed Web of Science ®Google Scholar
• Brofman BL. Medical evaluation of the Beck operation for coronary artery disease. JAMA. 1956;162:1603–1606.
   PubMed Web of Science ®Google Scholar
• Meerbaum S, Lang TW, Osher JV, et al. Diastolic retroperfusion of acutely ischemic myocardium. Am J Cardiol. 1976;37:588–598.
   PubMed Web of Science ®Google Scholar
• Farcot JC, Meerbaum S, Lang TW, et al. Synchronized retroperfusion of coronary veins for circulatory support of jeopardized ischemic myocardium. Am J Cardiol. 1978;41:1191–1201.
   PubMed Web of Science ®Google Scholar
• Chang BL, Drury JK, Meerbaum S, et al. Enhanced myocardial washout and retrograde blood delivery with synchronized retroperfusion during acute myocardial ischemia. J Am Coll Cardiol. 1987;9:1091–1098.
   PubMed Web of Science ®Google Scholar
• Mohl W. The development and rationale of pressure-controlled intermittent coronary sinus occlusion–a new approach to protect ischemic myocardium. Wien Klin Wochenschr. 1984;96:20–25.
   PubMed Web of Science ®Google Scholar
• Khattab AA, Stieger S, Kamat PJ, et al. Effect of pressure-controlled intermittent coronary sinus occlusion (PICSO) on myocardial ischaemia and reperfusion in a closed-chest porcine model. EuroIntervention. 2013;9:398–406.
   PubMed Web of Science ®Google Scholar
• Van De Hoef TP, Nijveldt R, Van Der Ent M, et al. Pressure- controlled intermittent coronary sinus occlusion (PICSO) in acute ST-segment elevation myocardial infarction: results of the Prepare RAMSES safety and feasibility study. EuroIntervention. 2015;11:37–44.
   PubMed Web of Science ®Google Scholar
• Paz Y, Shinfeld A. Letter to editor. Re: “Interventional treatment of pain in refractory angina. A Review” by Milos Dobias et al. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2014;158(3):486–487.
   PubMed Web of Science ®Google Scholar
• Banai S, Ben Muvhar S, Parikh KH, et al. Coronary sinus reducer stent for the treatment of chronic refractory angina pectoris: a prospective, open-label, multicenter, safety feasibility first-in-man study. J Am Coll Cardiol. 2007;49:1783–1789. .
   PubMed Web of Science ®Google Scholar
• Verheye S, Jolicoeu R, Behan MW, et al. Efficacy of a device to narrow the coronary sinus in refractory angina. N Engl J Med. 2015;372:519–527.
   PubMed Web of Science ®Google Scholar
• Ido A, Hasebe N, Matsuhashi H, et al. Coronary sinus occlusion enhances coronary collateral flow and reduces subendocardial ischemia. Am J Physiol Heart Circ Physiol. 2001;280:H1361–7.
   PubMed Web of Science ®Google Scholar
• Beyar R, Guerci AD, Halperin HR, et al. Intermittent coronary sinus occlusion after coronary arterial ligation results in venous retroperfusion. Circ Res. 1989;65:695–707.
   PubMed Web of Science ®Google Scholar
• Konigstein M, Meyten N, Verheye S, et al. Transcatheter treatment for refractory angina with the Coronary Sinus Reducer. EuroIntervention. 2014;9:1158–1164.
   PubMed Web of Science ®Google Scholar
• Abawi M, Nijhoff F, Doevendans PA, et al. Safety and efficacy of a device to narrow the coronary sinus for the treatment of refractory angina: a single-centre real-world experience. Neth Heart J. 2016;24(9):544–551.
   PubMed Web of Science ®Google Scholar
• Mak GS, Hill AJ, Moisiuc F, et al. Variations in Thebesian valve anatomy and coronary sinus ostium: implications for invasive electrophysiology procedures. Europace. 2009;11:1188–1192.
   PubMed Web of Science ®Google Scholar
• Karaca M, Bilge O, Dinckal MH, et al. The anatomic barriers in the coronary sinus: implications for clinical procedures. J Interv Card Electrophysiol. 2005;14:89–94.
   PubMed Web of Science ®Google Scholar